Postmarket Surveillance of Medical Devices: A Comparison of Strategies in the US, EU, Japan, and China

1. United States Food and Drug Administration (2013) Medical Devices: Is the Product a Medical Devices? Available: http://www.fda.gov/medicaldevices/deviceregulationandguidance/overview/classifyyourdevice/ucm051512.htm. Accessed 8 August 2013.

2. World Health Organization: Medical Devices. Available: http://www.who.int/medical_devices/en/. Accessed 8 August 2013.

3. HauserRG, KallinenLM, AlmquistAK, GornickCC, KatsiyiannisWT (2007) Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm 4: 892–896.

4. HauserRG, AbdelhadiR, McGriffD, RetelLK (2012) Deaths caused by the failure of Riata and Riata ST implantable cardioverter-defibrillator leads. Heart Rhythm 9: 1227–1235.

5. JamesonSS, BakerPN, MasonJ, PorterML, DeehanDJ, ReedMR (2012) Independent predictors of revision following metal-on-metal hip resurfacing: a retrospective cohort study using National Joint Registry data. J Bone Joint Surg Br 94: 746–754.

6. HortonR (2012) A serious regulatory failure, with urgent implications. Lancet 379: 106.

7. KramerDB, XuS, KesselheimAS (2012) How does medical device regulation perform in the United States and the European union? A systematic review. PLoS Med 9: e1001276 doi:10.1371/journal.pmed.1001276

8. United States Food and Drug Administration (2013) Code of Federal Regulations Title 21, Part 820. Quality Systems Regulation. Available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=820. Accessed 25 February 2013.

9. United States Food and Drug Administration (2013) Code of Federal Regulations Title 21, Part 803, Subpart A. Medical Device Reporting, General Provisions. Available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=803&showFR=1. Accessed 26 August 2013.

10. MaiselWH (2004) Medical device regulation: an introduction for the practicing physician. Ann Intern Med 140: 296–302.

11. United States Food and Drug Administration (2013) 522 Postmarket Surveillance Studies. Available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pss.cfm. Accessed 25 February 2013.

12. Food and Drug Administration (2010) CDRH preliminary internal evaluations—volume II. Task Force on the Utilization of Science in Regulatory Decision Making. Preliminary Report and Recommendations, August 2010. Available: http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/UCM220783.pdf. Accessed 8 August 2013.

13. United States Food and Drug Administration (2013) Post-Approval Studies website. Available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma_pas.cfm. Accessed 25 February 2013.

14. United States Food and Drug Administration (2013) 522 Postmarket Surveillance Studies. Available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pss.cfm. Accessed 7 July 2013.

15. United States Food and Drug Administration (2009) Safety – Background and Definitions. Available: http://www.fda.gov/Safety/Recalls/ucm165546.htm. Accessed 25 February 2013.

16. United States Food and Drug Administration (2012) Cardiac Science Powerheart, CardioVive, CardioLife; GE Responder and Responder Pro; and Nihon-Kohden Automated External Defibrillators (AEDs): Class I Recall - Defective Component. Available: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm294538.htm. Accessed 25 February 2013.

17. United States Food and Drug Administration (2013) Medical Devices – Recalls Specific to Metal-on-Metal Hip Implants. Available: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/MetalonMetalHipImplants/ucm241770.htm. Accessed 25 February 2013.

18. WilsonNA, DrozdaJ (2013) Value of unique device identification in the digital health infrastructure. JAMA 309: 2107–21088.

19. GrossTP, CrowleyJ (2012) Unique device identification in the service of public health. N Engl J Med 367: 1583–1585.

20. European Commission (2009) Guidelines on medical devices. Clinical evaluation: a guide for manufacturers and notified bodies. December 2009. Available: http://ec.europa.eu/health/medical-devices/files/meddev/2_7_1rev_3_en.pdf. Accessed 25 February 2013.

21. Pharmaceuticals and Medical Device Agency, Japan (2013) Overview of Services 2012-2013. Available: http://www.pmda.go.jp/english/about/pdf/profile_of_services.pdf. Accessed 7 July 2013.

22. Pharmaceuticals and Medical Devices Agency (2012) Pharmaceutical Affairs Law 77-4-2.

23. Pharmaceuticals and Medical Devices Agency, Japan (2013) Approved Products databases. Available: http://www.pmda.go.jp/english/service/approved.html. Accessed 7 July 2013.

24. English Regulatory Information Task Force for the Japan Pharmaceutical Manufacturers Association (2011) Pharmaceutical Administration and Regulations in Japan, March 2011. Available: http://www.nihs.go.jp/mhlw/yakuji/yakuji-e_20110502-02.pdf. Accessed July 17, 2013.

25. China Food and Drug Administration, PR China. Regulations for the Supervision and Administration of Medical Devices. Available: http://eng.sfda.gov.cn/WS03/CL0767/61641.html. Accessed 9 July 2013.

26. Gaffney A (2013) China's SFDA Becomes CFDA amidst Consolidation of Power and New Leadership. Regulatory Focus. Available: http://www.raps.org/focus-online/news/news-article-view/article/3073/chinas-sfda-becomes-cfda-amidst-consolidation-of-power-and-new-leadership.aspx. Accessed 9 July 2013.

27. Gaffney A (2013) Consolidation of China's SFDA Grants Agency More Prestige, Power. Regulatory Focus. Available: http://www.raps.org/focus-online/news/news-article-view/article/2993/consolidation-of-chinas-sfda-grants-agency-more-prestige-power.aspx. Accessed July 9, 2013.

28. State Food and Drug Administration, PR China. Affiliated Organizations. Available: http://former.sfda.gov.cn/cmsweb/webportal/W45255828/index.html. Accessed 25 February 2013.

29. Adverse Medical Event Reporting Process. Center for Drug Reevaluation, SFDA. Available: http://www.cdr.gov.cn/bszn/kyylqxblsjbglc/. Accessed 25 February 2013.

30. Gambrill S. China's Pharmacovigilance System: The Hunger for Safety Insights. Available: http://www.lifescienceleader.com/blogs/contributing-editors-2/item/3896-china%E2%80%99s-pharmacovigilance-system-the-hunger-for-safety-insights. Accessed 25 February 2013.

31. Austin S, Bass S, Stansel JC, Davis MW, Kalb PE, et al.. (2013) China develops new rules to simplify medical device re-registration process. Sidley Austin LLP Updates. Available: http://www.lexology.com/library/detail.aspx?g=70f3fdd2-c719-4a8c-99bb-2ffb670f08ee. Accessed 9 July 2013.

32. CFDA Drug Registration Regulations. Available: http://www.sfda.gov.cn/WS01/CL0053/24529.html. Accessed 9 July 2013.

33. XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study. Available: http://clinical-trials.findthedata.org/l/31815/XIENCE-V-Everolimus-Eluting-Coronary-Stent-System-EECSS-China-Post-Approval-Single-Arm-Study. Accessed 25 February 2013.

34. Center for Drug Reevaluation, SFDA (2011) Tentative Measures on the Administration of Recalls concerning Medical Devices, May 20, 2011. Available: http://eng.sfda.gov.cn/WS03/CL0757/63160.html. Accessed 28 August 2013.

35. (2012) SFDA to enforce Blacklist System for unsafe drug and device products. Sidley Austin LLP Updates. August 21, 2012. Available: http://www.sidley.com/SFDA-to-Enforce-Blacklist-System--for-Unsafe-Drug-and-Device-Products-08-21-2012/. Accessed 25 February 2013.

36. Liang Y (2010) Implementation of a postmarket traceability program for implantable medical devices adopting unique device identification. 2009-2012 GS1 Healthcare Reference Book. Available: http://www.gs1.org/docs/healthcare/case_studies/Case%20study_Shanghai%20FDA_IMD%20Traceability.pdf. Accessed 25 February 2013.

37. Camron Health, INC. (2012) Post approval study plan for the S-ICD System. Available: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM301241.pdf. Accessed 20 May 2013.

38. ClinicalTrials.gov (2013) S-ICD system post-approval study. Available: http://clinicaltrials.gov/ct2/show/NCT01736618. Accessed 20 May 2013.

39. United States Food and Drug Administration (2013) Post-Approval Studies. Available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma_pas.cfm. Accessed 20 May 2013.

40. Olde NordkampLR, Dabiri AbkenariL, BoersmaLV, MaassAH, deGrootJR, et al. (2012) The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. J Am Coll Cardiol 69: 1933–1939.

41. KöbeJ, ReinkeF, MeyerC, ShinDI, MartensE, et al. (2013) Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. Heart Rhythm 10: 29–36.

42. Clinical Device Group. Clinical Evaluation Reports Now Required for All Medical Devices in Europe. Available: http://www.clinicaldevice.com/09-09-14_Clinical_Evaluation_Report_Whitepaper.htm

43. United States Food and Drug Administration. CDRH Advisory Meeting Materials Archive, Circulatory Systems Advisory Panel, December 7-8 2006. Available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfadvisory/details.cfm?mtg=672. Accessed 25 February 2013.

44. WartmanGJ (2009) Life after Riegel: a fresh look at medical device preemption one year after Riegel v. Medtronic, Inc. Food Drug Law J 64: 291–311.

45. US Food and Drug Administration. Circulatory Systems Advisory Panel Meeting, April 26 2012. Sponsor presentation: Cameron Health S-ICD System. Available: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM302186.pdf. Accessed 9 September 2013.